Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Rating of “Hold” from Analysts

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have received a consensus rating of “Hold” from the five research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $9.3333.

Several brokerages recently commented on AYTU. Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 31st. Ascendiant Capital Markets increased their target price on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Friday, January 9th. Finally, Wall Street Zen raised Aytu BioPharma to a “hold” rating in a report on Saturday, February 7th.

Hedge Funds Weigh In On Aytu BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Daytona Street Capital LLC bought a new position in shares of Aytu BioPharma in the 4th quarter valued at $26,000. Rothschild Wealth LLC acquired a new position in Aytu BioPharma during the 4th quarter worth about $52,000. Dimensional Fund Advisors LP acquired a new position in shares of Aytu BioPharma in the 3rd quarter valued at about $58,000. Bellevue Asset Management LLC acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at about $65,000. Finally, XTX Topco Ltd acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at about $67,000. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Stock Down 0.7%

NASDAQ:AYTU opened at $2.66 on Tuesday. The company has a market cap of $28.54 million, a PE ratio of -0.69 and a beta of 0.27. The stock has a 50-day simple moving average of $2.51 and a 200 day simple moving average of $2.39. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. Aytu BioPharma has a 52-week low of $0.95 and a 52-week high of $3.07.

Aytu BioPharma (NASDAQ:AYTU) last released its earnings results on Tuesday, February 3rd. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The firm had revenue of $15.17 million during the quarter, compared to the consensus estimate of $12.17 million.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.